JPWO2019175113A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019175113A5 JPWO2019175113A5 JP2020572608A JP2020572608A JPWO2019175113A5 JP WO2019175113 A5 JPWO2019175113 A5 JP WO2019175113A5 JP 2020572608 A JP2020572608 A JP 2020572608A JP 2020572608 A JP2020572608 A JP 2020572608A JP WO2019175113 A5 JPWO2019175113 A5 JP WO2019175113A5
- Authority
- JP
- Japan
- Prior art keywords
- malignant
- tumor
- cancer
- adenocarcinoma
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011510 cancer Diseases 0.000 claims 30
- 230000003211 malignant Effects 0.000 claims 28
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 210000004027 cells Anatomy 0.000 claims 14
- 230000003042 antagnostic Effects 0.000 claims 13
- 239000005557 antagonist Substances 0.000 claims 13
- 208000009956 Adenocarcinoma Diseases 0.000 claims 11
- 206010024324 Leukaemias Diseases 0.000 claims 9
- -1 Aldophosphamide glycosides Chemical class 0.000 claims 8
- 235000020827 calorie restriction Nutrition 0.000 claims 8
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 8
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 8
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hibiscus acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims 7
- 238000002512 chemotherapy Methods 0.000 claims 7
- 229940089491 hydroxycitric acid Drugs 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 5
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 5
- 206010025650 Malignant melanoma Diseases 0.000 claims 5
- 229960001592 Paclitaxel Drugs 0.000 claims 5
- 206010039491 Sarcoma Diseases 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 5
- 230000003278 mimic Effects 0.000 claims 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 5
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 229960004562 Carboplatin Drugs 0.000 claims 4
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 4
- 229960002949 Fluorouracil Drugs 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 206010025310 Other lymphomas Diseases 0.000 claims 4
- 229960003048 Vinblastine Drugs 0.000 claims 4
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 201000000053 blastoma Diseases 0.000 claims 4
- 201000008184 embryoma Diseases 0.000 claims 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 4
- 235000019136 lipoic acid Nutrition 0.000 claims 4
- 229960001756 oxaliplatin Drugs 0.000 claims 4
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 claims 4
- 229960005079 pemetrexed Drugs 0.000 claims 4
- 229960002663 thioctic acid Drugs 0.000 claims 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 4
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 3
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 3
- 229950002916 Avelumab Drugs 0.000 claims 3
- 229960000975 Daunorubicin Drugs 0.000 claims 3
- 210000003298 Dental Enamel Anatomy 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229960004679 Doxorubicin Drugs 0.000 claims 3
- 229950009791 Durvalumab Drugs 0.000 claims 3
- 229960001904 EPIRUBICIN Drugs 0.000 claims 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 3
- 108010089187 Ipilimumab Proteins 0.000 claims 3
- 229960001156 Mitoxantrone Drugs 0.000 claims 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 3
- 108010019706 Nivolumab Proteins 0.000 claims 3
- 229950010773 Pidilizumab Drugs 0.000 claims 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 3
- 229950007217 Tremelimumab Drugs 0.000 claims 3
- 229960004528 Vincristine Drugs 0.000 claims 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 108010072668 atezolizumab Proteins 0.000 claims 3
- 229960003852 atezolizumab Drugs 0.000 claims 3
- 108010010826 avelumab Proteins 0.000 claims 3
- 230000003115 biocidal Effects 0.000 claims 3
- 201000009030 carcinoma Diseases 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 108010016436 durvalumab Proteins 0.000 claims 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 229940079866 intestinal antibiotics Drugs 0.000 claims 3
- 229960005386 ipilimumab Drugs 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 3
- 108010026276 pembrolizumab Proteins 0.000 claims 3
- 229960002621 pembrolizumab Drugs 0.000 claims 3
- 108010051812 pidilizumab Proteins 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- 210000004500 stellate cell Anatomy 0.000 claims 3
- 229930003347 taxol Natural products 0.000 claims 3
- 108010072993 tremelimumab Proteins 0.000 claims 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 3
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 102100005310 CTLA4 Human genes 0.000 claims 2
- 101700054183 CTLA4 Proteins 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- 229960004117 Capecitabine Drugs 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 229960000640 Dactinomycin Drugs 0.000 claims 2
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N Gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 claims 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 2
- 206010020243 Hodgkin's disease Diseases 0.000 claims 2
- BTXNYTINYBABQR-UHFFFAOYSA-N Hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims 2
- 229960000908 Idarubicin Drugs 0.000 claims 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical class C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 2
- 208000004019 Papillary Adenocarcinoma Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N Spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 2
- 208000005400 Synovial Cyst Diseases 0.000 claims 2
- 229960005454 Thioguanine Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229940045698 antineoplastic Taxanes Drugs 0.000 claims 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 2
- 108010075600 citrate-binding transport protein Proteins 0.000 claims 2
- 201000008808 fibrosarcoma Diseases 0.000 claims 2
- 230000003325 follicular Effects 0.000 claims 2
- 201000005160 follicular thyroid carcinoma Diseases 0.000 claims 2
- 230000000762 glandular Effects 0.000 claims 2
- 150000004676 glycans Polymers 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- 230000002438 mitochondrial Effects 0.000 claims 2
- 201000010225 mixed cell type cancer Diseases 0.000 claims 2
- 201000010133 oligodendroglioma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 150000004804 polysaccharides Polymers 0.000 claims 2
- LDLGBNXSBZFATB-BYPYZUCNSA-N (2S)-5-amino-2-(difluoromethylamino)pentanoic acid Chemical compound NCCC[C@@H](C(O)=O)NC(F)F LDLGBNXSBZFATB-BYPYZUCNSA-N 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 claims 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7S,9R,10R)-7-[(2R,4S,5S,6S)-5-[[(2S,4aS,5aS,7S,9S,9aR,10aR)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2S,4S,5S,6S)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 claims 1
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 claims 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 claims 1
- AESVUZLWRXEGEX-GJPCMZTKSA-N (7S,9S)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;iron(3+) Chemical compound [Fe+3].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1C[C@@H](N)[C@@H](O)[C@@H](C)O1 AESVUZLWRXEGEX-GJPCMZTKSA-N 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-N-[(3S,6S,7R,10S,16S)-3-[(2S)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-N-[(3S,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 claims 1
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-N,N-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 claims 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-N,N-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 claims 1
- YIMDLWDNDGKDTJ-ABYLTEMBSA-N 4-[(2S,3S,4S)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]morpholine-3-carbonitrile Chemical compound N1([C@H]2CC(O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-ABYLTEMBSA-N 0.000 claims 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N 5-ethynyl-1H-pyrimidine-2,4-dione Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 208000004804 Adenomatous Polyps Diseases 0.000 claims 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 1
- 229960003896 Aminopterin Drugs 0.000 claims 1
- 229960001220 Amsacrine Drugs 0.000 claims 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims 1
- 102100009333 BTLA Human genes 0.000 claims 1
- 101700047069 BTLA Proteins 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 claims 1
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O Bleomycin Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 208000007690 Brenner Tumor Diseases 0.000 claims 1
- 206010073258 Brenner tumour Diseases 0.000 claims 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- 102100007290 CD274 Human genes 0.000 claims 1
- 229950009908 Cactinomycin Drugs 0.000 claims 1
- 229960004203 Carnitine Drugs 0.000 claims 1
- 208000009667 Cerebral sarcoma Diseases 0.000 claims 1
- 229960004630 Chlorambucil Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 210000004252 Chorionic Villi Anatomy 0.000 claims 1
- 208000009060 Clear Cell Adenocarcinoma Diseases 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- PSNOPSMXOBPNNV-VVCTWANISA-N Cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 claims 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N Digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 claims 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 claims 1
- LTMHDMANZUZIPE-PUGKRICDSA-N Digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 108010036824 EC 4.1.3.6 Proteins 0.000 claims 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N ESORUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 210000003989 Endothelium, Vascular Anatomy 0.000 claims 1
- 229950010213 Eniluracil Drugs 0.000 claims 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 claims 1
- 210000002615 Epidermis Anatomy 0.000 claims 1
- 229950002017 Esorubicin Drugs 0.000 claims 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N Esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 claims 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Etoglucid Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 claims 1
- 229960005237 Etoglucid Drugs 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 229960000304 Folic Acid Drugs 0.000 claims 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 102100016384 HAVCR2 Human genes 0.000 claims 1
- 101710004393 HAVCR2 Proteins 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 229940015872 Ibandronate Drugs 0.000 claims 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 108060004270 LAG3 Proteins 0.000 claims 1
- 102100017213 LAG3 Human genes 0.000 claims 1
- 229920001491 Lentinan Polymers 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 206010024627 Liposarcoma Diseases 0.000 claims 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N Lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 claims 1
- 210000002751 Lymph Anatomy 0.000 claims 1
- 210000004698 Lymphocytes Anatomy 0.000 claims 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 208000007369 Malignant Mixed Tumor Diseases 0.000 claims 1
- 208000008688 Malignant mesenchymal tumor Diseases 0.000 claims 1
- 208000003393 Mammary Paget's Disease Diseases 0.000 claims 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N Mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 claims 1
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 1
- 210000004379 Membranes Anatomy 0.000 claims 1
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 claims 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N Methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 claims 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 claims 1
- 102000038177 Mitochondrial pyruvate carriers Human genes 0.000 claims 1
- 108091007348 Mitochondrial pyruvate carriers Proteins 0.000 claims 1
- 229960004857 Mitomycin Drugs 0.000 claims 1
- 229960000951 Mycophenolic Acid Drugs 0.000 claims 1
- 206010028549 Myeloid leukaemia Diseases 0.000 claims 1
- 241000232901 Nephroma Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029273 Neurofibrosarcomas Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- 101710011976 PDCD1LG2 Proteins 0.000 claims 1
- 102100007289 PDCD1LG2 Human genes 0.000 claims 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims 1
- 229950010131 PUROMYCIN Drugs 0.000 claims 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 claims 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 claims 1
- 208000007312 Paraganglioma Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 1
- 229950004892 Rodorubicin Drugs 0.000 claims 1
- 101700061430 SAT19 Proteins 0.000 claims 1
- 208000000097 Sertoli-Leydig Cell Tumor Diseases 0.000 claims 1
- 108091019225 Short-chain family Proteins 0.000 claims 1
- 210000000278 Spinal Cord Anatomy 0.000 claims 1
- 206010062261 Spinal cord neoplasm Diseases 0.000 claims 1
- 229950006315 Spirogermanium Drugs 0.000 claims 1
- 206010042863 Synovial sarcoma Diseases 0.000 claims 1
- 101700081234 TTR Proteins 0.000 claims 1
- 229960001278 Teniposide Drugs 0.000 claims 1
- KLBSRSYHIIAQTG-PZICIZFRSA-N Tenuazonic acid Chemical compound CC[C@H](C)[C@@H]1NC(=O)C(C(C)=O)C1=O KLBSRSYHIIAQTG-PZICIZFRSA-N 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 229960001196 Thiotepa Drugs 0.000 claims 1
- 210000001685 Thyroid Gland Anatomy 0.000 claims 1
- 208000009955 Thyroid Neoplasms Diseases 0.000 claims 1
- 229960001727 Tretinoin Drugs 0.000 claims 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims 1
- 229960001099 Trimetrexate Drugs 0.000 claims 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 claims 1
- 229950009811 UBENIMEX Drugs 0.000 claims 1
- 102100015314 VSIR Human genes 0.000 claims 1
- 101710036075 VSIR Proteins 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
- 241000863480 Vinca Species 0.000 claims 1
- 229940053867 Xeloda Drugs 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000001919 adrenal Effects 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N aldehydo-D-arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 1
- 229930013930 alkaloids Natural products 0.000 claims 1
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 1
- 229960002749 aminolevulinic acid Drugs 0.000 claims 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims 1
- 201000003076 angiosarcoma Diseases 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 201000007436 apocrine adenocarcinoma Diseases 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- 201000011143 bone giant cell tumor Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000005217 chondroblastoma Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 108010006226 cryptophycin Proteins 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960000648 digitoxin Drugs 0.000 claims 1
- 229960005156 digoxin Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 230000003511 endothelial Effects 0.000 claims 1
- 210000002919 epithelial cells Anatomy 0.000 claims 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2S)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 claims 1
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
- 230000001605 fetal Effects 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 230000002538 fungal Effects 0.000 claims 1
- 229940044658 gallium nitrate Drugs 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 210000004565 granule cell Anatomy 0.000 claims 1
- 230000002440 hepatic Effects 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 239000003396 histamine H4 receptor antagonist Substances 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- 229940027318 hydroxyurea Drugs 0.000 claims 1
- 229940005608 hypericin Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 1
- 229940115286 lentinan Drugs 0.000 claims 1
- 229960001518 levocarnitine Drugs 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 229960003538 lonidamine Drugs 0.000 claims 1
- 230000001926 lymphatic Effects 0.000 claims 1
- 201000006439 lymphocytic leukemia Diseases 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 229950008612 mannomustine Drugs 0.000 claims 1
- 201000008749 mast-cell sarcoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960005485 mitobronitol Drugs 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000004458 myoma Diseases 0.000 claims 1
- 229950009266 nogalamycin Drugs 0.000 claims 1
- MAZYQGHSTXUZJF-ZBRHGPMOSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](O)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@]5(C)C[C@H](C[C@@H](O5)CC4=C3C3=O)N(C)C)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 MAZYQGHSTXUZJF-ZBRHGPMOSA-N 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- 229960000952 pipobroman Drugs 0.000 claims 1
- 229960001221 pirarubicin Drugs 0.000 claims 1
- 229960000624 procarbazine Drugs 0.000 claims 1
- 150000003212 purines Chemical class 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 229960000460 razoxane Drugs 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 230000002207 retinal Effects 0.000 claims 1
- 235000020945 retinal Nutrition 0.000 claims 1
- 239000011604 retinal Substances 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims 1
- 230000001568 sexual Effects 0.000 claims 1
- 229940063673 spermidine Drugs 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Claims (16)
- 化学療法及び免疫チェックポイント阻害剤と組み合わせて、それを必要とする患者の癌の治療において使用するための医薬組成物であって、前記医薬組成物が少なくとも1つのカロリー制限模倣物を含む、医薬組成物。
- 前記少なくとも1つのカロリー制限模倣物が、ミトコンドリアピルビン酸担体複合体(MPC)の阻害剤、ミトコンドリアカルニチンパルミチン酸転移酵素-1(CTP1)の阻害剤、ミトコンドリアクエン酸担体(CiC)の阻害剤、ATP-クエン酸リアーゼ(ACLY)の阻害剤、EP300アセチルトランスフェラーゼ阻害剤、及びアシル-CoA合成酵素短鎖ファミリーメンバー2(ACCS2)の阻害剤からなる群から選択される、請求項1に記載の医薬組成物。
- 前記少なくとも1つのカロリー制限模倣物が、ヒドロキシクエン酸、リポ酸、スペルミジン、それらの医薬として許容される塩、及びそれらの混合物からなる群から選択される、請求項1又は2に記載の医薬組成物。
- 前記少なくとも1つのカロリー制限模倣物が、ヒドロキシクエン酸又はその医薬として許容される塩である、請求項1~3のいずれか一項に記載の医薬組成物。
- 前記少なくとも1つのカロリー制限模倣物が、リポ酸に関連付けられるヒドロキシクエン酸又はその医薬として許容される塩である、請求項1~3のいずれか一項に記載の医薬組成物。
- 前記化学療法が、アルキル化剤;アルキルスルホン酸塩;アジリジン類;エチレンイミン類;メチルアメラミン類;アセトゲニン類;カンプトテシン;ブリオスタチン;カリスタチン;CC-1065;クリプトフィシン類;ドラスタチン;デュオカルマイシン;エレウテロビン;パンクラチスタチン;サルコジクチン;スポンジスタチン;ナイトロジェンマスタード;ニトロソウレア;抗生物質;エンジイン抗生物質;ダイネミシン;ビスホスホネート類;エスペラミシン;ネオカルジノスタチンクロモフォア及び関連クロモプロテインエンジイン抗生物質クロモフォア、アクラシノマイシン類、アクチノマイシン、オースラルナイシン、アザセリン、ブレオマイシン類、カクチノマイシン、カラビシン、カミノマイシン、カルジノフィリン、クロモマイシン類、ダクチノマイシン、ダウノルビシン、デトルビシン、6-ジアゾ-5-オキソ-L-ノルロイシン、ドキソルビシン、エピルビシン、エソルビシン、イダルビシン、マルセロマイシン、マイトマイシン類、ミコフェノール酸、ノガラマイシン、オリボマイシン類、ペプロマイシン、ポルフィロマイシン、ピューロマイシン、ケラマイシン(quelamycin)、ロドルビシン、ストレプトニグリン、ストレプトゾシン、ツベルシジン、ウベニメックス、ジノスタチン、ゾルビシン;抗代謝拮抗薬;5-フルオロウラシル(5-FU);葉酸類似体;プリン類似体;ピリミジン類似体;アンドロゲン類;抗副腎剤類;葉酸補充剤;アセグラトン;アルドホスファミドグリコシド;アミノレブリン酸;エニルウラシル;アムサクリン;ベストラブシル;ビサントレン;エダトラキサート(edatraxate);デフォファミン(defofamine);デメコルシン;ジアジコン;エルフォルミチン(elformithine);酢酸エリプチニウム;エポチロン;エトグルシド;硝酸ガリウム;ヒドロキシウレア;レンチナン;ロニダイニン(lonidainine);メイタンシノイド類;ミトグアゾン;ミトキサントロン;モピダンモール(mopidanmol);ニトラエリン(nitraerine);ペントスタチン;フェナメト(phenamet);ピラルビシン;ロソキサントロン;ポドフィリン酸;2-エチルヒドラジド;プロカルバジン;PSK多糖複合体;ラゾキサン;リゾキシン;シゾフラン;スピロゲルマニウム;テヌアゾン酸;トリアジコン;2,2’,2’’-トリクロロトリエチルアミン;トリコテセン類;ウレタン;ビンデシン;ダカルバジン;マンノムスチン;ミトブロニトール;ミトラクトール;ピポブロマン;ガシトシン;アラビノシド(「Ara-C」);シクロホスファミド;チオテパ;タキソイド類;クロラムブシル;ゲムシタビン;6-チオグアニン;メルカプトプリン;メトトレキサート;白金配位錯体;ビンブラスチン;白金;エトポシド(VP‐16);イホスファミド;ビンクリスチン;ビノレルビン;テニポシド;エダトレキサート;ダウノマイシン;アミノプテリン;ゼローダ;イバンドロネート;イリノテカン;トポイソメラーゼ阻害剤RFS2000;ジフルオロメチルオルニチン(DMFO);レチノイド類;カペシタビン;ペメトレキセド;並びに上記のいずれかの医薬として許容される塩、酸又は誘導体からなる群から選択される、請求項1~5のいずれか一項に記載の医薬組成物。
- 前記化学療法は、シクロスホスファミド、ドラスタチン、パンクラチスタチン、メクロレタミン、ブレオマイシン類、ダクチノマイシン、ダウノルビシン、ドキソルビシン、モルホリノドキソルビシン、シアノモルホリノドキソルビシン、2-ピロリノドキソルビシン、デオキシドキソルビシン、エピルビシン、イダルビシン、5-フルオロウラシル、トリメトレキサート、エポチロン類、ロニダミン、メイタンシン、ミトキサントロン、PSK多糖複合体、ベルカリンA、ビンデシン、シトシンアラビノシド、パクリタキセル、nab-パクリタキセル、ドセタキセル、6-チオグアニン、シスプラチン、オキサリプラチン、カルボプラチン、ビンブラスチン、白金、アンサミトシン類、ビンクリスチン、ビノレルビン、ダウノマイシン、イリノテカン、レチノイン酸、ボルテゾミブ、ジギトキシン、ジゴキシン、パツピロン、ヒペリシン、セツキシマブ、セプタシジン、ヘダマイシン、CDDP、マイトマイシンC、テモゾロミド、ゲムシタビン及びペメトレキセドからなる群から選択される化学療法剤である、請求項1~5のいずれか一項に記載の医薬組成物。
- 前記免疫チェックポイント阻害剤が、PD-1アンタゴニスト、PD-L1アンタゴニスト、PD-L2アンタゴニスト、CTLA-4アンタゴニスト、VISTAアンタゴニスト、TIM-3アンタゴニスト、LAG-3アンタゴニスト、IDOアンタゴニスト、KIR2Dアンタゴニスト、A2ARアンタゴニスト、B7-H3アンタゴニスト、B7-H4アンタゴニスト、及びBTLAアンタゴニストからなる群から選択される、請求項1~7のいずれか一項に記載の医薬組成物。
- 前記免疫チェックポイント阻害剤が、PD-1アンタゴニストとCTLA-4アンタゴニストの治療上有効な組み合わせである、請求項1~8のいずれか一項に記載の医薬組成物。
- 前記免疫チェックポイント阻害剤が、ニボルマブ、ペンブロリズマブ、ピディリズマブ、アベルマブ、デュルバルマブ、アテゾリズマブ、イピリムマブ及びトレメリムマブからなる群から選択される、請求項1~9のいずれか一項に記載の医薬組成物。
- 前記少なくとも1つのカロリー制限模倣物が、ヒドロキシクエン酸又はリポ酸に関連付けられるヒドロキシクエン酸である;
前記化学療法が、シスプラチン、オキサリプラチン、カルボプラチン;パクリタキセル、nab-パクリタキセル、及びドセタキセルから選択されるタキサン類;ビンデシン、ビンブラスチン、ビンクリスチン及びビノレルビンから選択されるビンカアルカロイド類;ミトキサントロン、ダウノルビシン、ドキソルビシン、エピルビシン、イダルビシン、バルルビシン及びジトリサルビシンから選択されるアントラサイクリン類;ゲムシタビン;ペメトレキセド;それらの混合物及びそれらの医薬として許容される塩から選択される化学療法剤である;かつ
前記免疫チェックポイント阻害剤が、ニボルマブ、ペンブロリズマブ、ピディリズマブ、アベルマブ、デュルバルマブ、アテゾリズマブ、イピリムマブ及びトレメリムマブからなる群から選択される、
請求項1~10のいずれか一項に記載の医薬組成物。 - 前記少なくとも1つのカロリー制限模倣物が、ヒドロキシクエン酸又はリポ酸に関連付けられるヒドロキシクエン酸である;
前記化学療法が、シスプラチン、オキサリプラチン、カルボプラチン;カルボプラチン及びペメトレキセドの同時若しくは逐次的な組み合わせ;オキサリプラチン及び5-FUの同時若しくは逐次的な組み合わせ;パクリタキセル、nab-パクリタキセル、及びドセタキセルから選択されるタキサン類;ゲムシタビン、ペメトレキセド、ミトキサントロン;並びにそれらの混合物及びそれらの医薬として許容される塩から選択される化学療法剤である;かつ
前記免疫チェックポイント阻害剤が、ニボルマブ、ペンブロリズマブ、ピディリズマブ、アベルマブ、デュルバルマブ、アテゾリズマブ、イピリムマブ及びトレメリムマブからなる群から選択される、請求項1~10のいずれか一項に記載の医薬組成物。 - 前記医薬組成物が、前記化学療法及び/又は前記免疫チェックポイント阻害剤と同時に投与される、請求項1~12のいずれか一項に記載の医薬組成物。
- 前記医薬組成物が、前記化学療法及び/又は前記免疫チェックポイント阻害剤の前に投与される、請求項1~12のいずれか一項に記載の医薬組成物。
- 前記癌が、悪性の新生物、癌腫、未分化癌腫、巨細胞癌及び紡錘細胞癌、小細胞癌、乳頭癌、扁平上皮癌、リンパ上皮癌、基底細胞癌、石灰化上皮腫、移行上皮癌、乳頭移行上皮癌、腺癌、悪性の胃腸癌、胆管癌、肝細胞癌、複合肝細胞癌及び胆管癌、小柱腺癌、腺様嚢胞癌、腺腫性ポリープ中の腺癌、家族性大腸ポリポーシスの腺癌、固形癌、悪性のカルチノイド腫瘍、細気管支肺胞腺癌、乳頭腺癌、色素嫌性癌、好酸性癌、好酸性腺癌、好塩基性癌、明細胞腺癌、顆粒細胞癌、濾胞腺癌、乳頭腺癌及び濾胞腺癌、非被包性硬化性癌、副腎皮質癌、類内膜癌、皮膚付属器癌、アポクリン腺癌、脂腺癌、耳垢腺癌、粘膜表皮癌、嚢胞腺癌、乳頭状嚢腺癌、乳頭状漿液性嚢胞腺癌、粘液性嚢胞腺癌、粘液性腺癌、印環細胞癌、浸潤性腺管癌、髄様癌、小葉癌、炎症性癌、乳房のパジェット病、腺房細胞癌、腺扁平上皮癌、扁平上皮化生を伴う腺癌、悪性胸腺腫、悪性卵巣間質性腫瘍、悪性莢膜細胞腫、悪性顆粒膜細胞腫、悪性アンドロブラストーマ、セルトリ細胞癌、悪性ライディッヒ細胞腫、悪性脂質細胞腫、悪性傍神経節腫、悪性乳房外傍神経節腫、褐色細胞腫、血管球血管肉腫、悪性黒色腫、無色素性黒色腫、表在拡大型黒色腫、巨大色素性母斑中の悪性黒色腫、類上皮細胞黒色腫、悪性青色母斑、肉腫、線維肉腫、悪性線維性組織球腫、粘液肉腫、脂肪肉腫、平滑筋肉腫、横紋筋肉腫、胎児性横紋筋肉腫、胞巣状横紋筋肉腫、間質性肉腫、悪性混合腫瘍、ミュラー管混合腫瘍、腎芽腫、肝芽腫、癌肉腫、悪性間葉腫、悪性ブレンナー腫瘍、悪性葉状腫瘍、滑膜肉腫、悪性中皮腫、未分化胚細胞腫、胚性癌腫、悪性奇形腫、悪性卵巣甲状腺腫、絨毛癌、悪性中腎腫、血管肉腫、悪性血管内皮腫、カポジ肉腫、悪性血管内皮腫、リンパ管肉腫、骨肉腫、傍骨性骨肉腫、軟骨肉腫、悪性軟骨芽腫、間葉性軟骨肉腫、骨巨細胞腫、ユーイング肉腫、悪性歯原性腫瘍、エナメル上皮歯牙肉腫、悪性エナメル上皮腫、エナメル上皮線維肉腫、悪性松果体腫、脊索腫、悪性神経膠腫、上衣腫、星状細胞腫、形質性星状細胞腫、線維性星細胞腫、星芽腫、膠芽腫、乏突起膠腫、乏突起膠芽腫、原始神経外胚葉性、小脳肉腫、神経節神経芽腫、神経芽腫、網膜芽細胞腫、嗅神経腫瘍、悪性髄膜腫、神経線維肉腫、悪性神経線維鞘腫、悪性顆粒細胞腫、悪性リンパ腫、ホジキン病、ホジキンリンパ腫、側肉芽腫、悪性リンパ腫、小リンパ球性、悪性リンパ腫、びまん性大細胞型、濾胞性悪性リンパ腫、菌状息肉症、その他の特定されている非ホジキンリンパ腫、悪性組織球症、多発性骨髄腫、マスト細胞肉腫、免疫増殖性小腸疾患、白血病、リンパ性白血病、形質細胞性白血病、赤白血病、リンパ肉腫細胞白血病、骨髄性白血病、好塩基球性白血病、好酸球性白血病、単球性白血病、肥満細胞性白血病、巨核芽球性白血病、骨髄肉腫、及び毛髪様細胞白血病からなる群から選択される、請求項1~14のいずれか一項に記載の医薬組成物。
- a)化学療法剤、
b)免疫療法剤、及び
c)少なくとも1つのカロリー制限模倣物
を含むキット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18305257.0 | 2018-03-12 | ||
EP18305257 | 2018-03-12 | ||
EP18305359 | 2018-03-29 | ||
EP18305359.4 | 2018-03-29 | ||
PCT/EP2019/056041 WO2019175113A1 (en) | 2018-03-12 | 2019-03-11 | Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021517589A JP2021517589A (ja) | 2021-07-26 |
JPWO2019175113A5 true JPWO2019175113A5 (ja) | 2022-03-10 |
Family
ID=66102028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020572608A Pending JP2021517589A (ja) | 2018-03-12 | 2019-03-11 | 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210030703A1 (ja) |
EP (1) | EP3765085A1 (ja) |
JP (1) | JP2021517589A (ja) |
KR (1) | KR20210004966A (ja) |
CN (1) | CN112218658A (ja) |
AU (1) | AU2019236402A1 (ja) |
BR (1) | BR112020018585A8 (ja) |
CA (1) | CA3093742A1 (ja) |
RU (1) | RU2020133451A (ja) |
SG (1) | SG11202008696RA (ja) |
WO (1) | WO2019175113A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4059518A4 (en) * | 2019-11-13 | 2023-11-29 | Kyoto University | COMBINATION THERAPY WITH PD-1 SIGNAL INHIBITOR |
IT202000007153A1 (it) * | 2020-04-03 | 2021-10-03 | Ifom Fondazione St Firc Di Oncologia Molecolare | Apporto calorico ridotto e immunoterapia per il trattamento del cancro |
EP4349362A1 (en) * | 2021-05-28 | 2024-04-10 | Nippon Kayaku Kabushiki Kaisha | Combined use of ubenimex and immune checkpoint inhibitors |
WO2023288299A1 (en) * | 2021-07-15 | 2023-01-19 | Farber Partners, Llc | Use of methanol and prodrugs thereof in therapy |
CN115590187A (zh) * | 2021-10-08 | 2023-01-13 | 南京纽邦生物科技有限公司(Cn) | 通过施用二氢小檗碱模拟热量限制的生物学益处的方法和组合物 |
CN115721659A (zh) * | 2021-12-09 | 2023-03-03 | 苏州百迈生物医药有限公司 | 一种表柔比星复方制剂及其制备方法和应用 |
EP4197525A1 (en) * | 2021-12-20 | 2023-06-21 | Scandion Oncology A/S | Combination of drugs for the treatment of cancer |
CN115531555B (zh) * | 2022-08-19 | 2024-02-09 | 上海市第一人民医院 | 一种甘露糖修饰的纳米颗粒在制备治疗骨肉瘤药物中的应用 |
CN115282147A (zh) * | 2022-08-31 | 2022-11-04 | 深圳市宝安区人民医院 | 罗拉匹坦或/和罗拉匹坦衍生物在抗结核分枝杆菌药物中的应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
GB9209628D0 (en) | 1992-05-05 | 1992-06-17 | Smithkline Beecham Plc | Compounds |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
PL216630B1 (pl) | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
GB0229734D0 (en) | 2002-12-23 | 2003-01-29 | Qinetiq Ltd | Grading oestrogen and progesterone receptors expression |
US7257268B2 (en) | 2003-02-28 | 2007-08-14 | Aperio Technologies, Inc. | Systems and methods for image pattern recognition |
SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
PL2134689T3 (pl) | 2007-03-16 | 2014-10-31 | Scripps Research Inst | Inhibitory kinazy ognisk adhezyjnych |
CN101678215B (zh) | 2007-04-18 | 2014-10-01 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
US8023714B2 (en) | 2007-06-06 | 2011-09-20 | Aperio Technologies, Inc. | System and method for assessing image interpretability in anatomic pathology |
WO2009101611A1 (en) | 2008-02-11 | 2009-08-20 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
JP2011512413A (ja) | 2008-02-19 | 2011-04-21 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Fakの阻害剤としてのアニリノピリジン |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
AU2009261764B2 (en) | 2008-06-17 | 2013-01-10 | Astrazeneca Ab | Pyridine compounds |
JP2012510429A (ja) | 2008-08-25 | 2012-05-10 | アンプリミューン、インコーポレーテッド | Pd−1アンタゴニストおよびその使用方法 |
PE20110435A1 (es) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | Composiciones antagonistas del pd-1 |
CA2737116C (en) | 2008-09-16 | 2019-01-15 | Historx, Inc. | Reproducible quantification of biomarker expression |
US20140155410A1 (en) | 2008-10-27 | 2014-06-05 | Glaxosmithkline Llc | Pyrazolylaminopyridines as inhibitors of fak |
JO3067B1 (ar) | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
US20100120727A1 (en) * | 2008-11-12 | 2010-05-13 | Kyphia Pharmaceuticals, Inc. | Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
EP2417984B1 (en) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
US8289808B2 (en) | 2009-04-16 | 2012-10-16 | Chevron U.S.A., Inc. | System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole |
US20110111435A1 (en) | 2009-11-06 | 2011-05-12 | SlidePath Limited | Detecting Cell Surface Markers |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
EP2581113B1 (en) | 2010-06-11 | 2018-05-09 | Kyowa Hakko Kirin Co., Ltd. | Anti-tim-3 antibody |
AU2012210673B2 (en) | 2011-01-25 | 2015-12-24 | Air Products And Chemicals, Inc. | Gasification reactor |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
ES2675022T3 (es) | 2013-03-15 | 2018-07-05 | Bristol-Myers Squibb Company | Inhibidores de indolamina 2,3-dioxigenasa (IDO) |
MX365218B (es) | 2013-09-06 | 2019-05-27 | Aurigene Discovery Tech Ltd | Derivados de 1,2,4-oxadiazol como inmunomoduladores. |
CU24345B1 (es) | 2013-09-06 | 2018-05-08 | Aurigene Discovery Tech Ltd | Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores |
EP3052133A2 (en) * | 2013-10-03 | 2016-08-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof |
US10532056B2 (en) * | 2015-06-29 | 2020-01-14 | Verastem, Inc. | Therapeutic compositions, combinations, and methods of use |
-
2019
- 2019-03-11 EP EP19716299.3A patent/EP3765085A1/en active Pending
- 2019-03-11 SG SG11202008696RA patent/SG11202008696RA/en unknown
- 2019-03-11 US US16/980,003 patent/US20210030703A1/en active Pending
- 2019-03-11 AU AU2019236402A patent/AU2019236402A1/en active Pending
- 2019-03-11 KR KR1020207028067A patent/KR20210004966A/ko unknown
- 2019-03-11 WO PCT/EP2019/056041 patent/WO2019175113A1/en unknown
- 2019-03-11 JP JP2020572608A patent/JP2021517589A/ja active Pending
- 2019-03-11 RU RU2020133451A patent/RU2020133451A/ru unknown
- 2019-03-11 BR BR112020018585A patent/BR112020018585A8/pt unknown
- 2019-03-11 CA CA3093742A patent/CA3093742A1/en active Pending
- 2019-03-11 CN CN201980031861.7A patent/CN112218658A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shah et al. | Treatment of metastatic esophagus and gastric cancer | |
Jones et al. | A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma | |
Konings et al. | The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial | |
JP7032320B2 (ja) | 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用 | |
Mountzios et al. | Developments in the systemic treatment of metastatic cervical cancer | |
Lichtman | Chemotherapy in the elderly | |
JPWO2019175113A5 (ja) | ||
Crivellari et al. | New oral drugs in older patients: a review of idarubicin in elderly patients | |
Albertsson et al. | Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer | |
TWI492759B (zh) | 膽甾烷醇衍生物之併用用途 | |
Türkölmez et al. | Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy | |
Friedman et al. | Capsaicinoids enhance chemosensitivity to chemotherapeutic drugs | |
US10765675B2 (en) | Compositions and methods for treating Ewing family tumors | |
De Lange et al. | Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer | |
Fung et al. | What's new in pancreatic cancer treatment? | |
Dudek et al. | Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer | |
CN110893189A (zh) | 阿帕替尼与依托泊苷联合在制备治疗肺癌的药物中的用途 | |
Steinherz et al. | The prevention of anthracycline cardiomyopathy | |
TWI461199B (zh) | 膽甾烷醇衍生物之併用用途 | |
JP6820567B2 (ja) | 癌治療剤 | |
Singh et al. | A review on neoplastic diseases and their treatment | |
Hałka | Pixantrone–anticancer drug in the monotherapy of aggressive lymphomas | |
Iwuji | Translating curcumin into clinical practice for treatment of metastatic colorectal cancer: the CUFOX trial | |
Nio et al. | Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer | |
Huitzil-Melendez et al. | Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers |